THE BIOTECH GROWTH TRUST PLC (the "Company")

Results of the Annual General Meeting

The Board is pleased to announce that at the Annual General Meeting (AGM) of the Company held on Thursday, 27 July 2023 all resolutions as detailed below were duly passed by shareholders on a poll.

Resolutions	Votes For	%	Votes Against	%	Total Votes Cast	Votes Withheld*
To accept the audited financial statements and the Report of the Directors for the year ended 31 March 2023.	11,114,133	99.99	1,298	0.01	11,115,431	4,561
2. To approve the Directors' Remuneration Report for the year ended 31 March 2023.	, ,		,			,
	11,060,592	99.58	46,591	0.42	11,107,183	12,809
3. To approve the Directors' Remuneration Policy as set out on page 64 of the Annual Report for the year ended 31 March 2023.	11,056,570	99.54	50,613	0.46	11,107,183	12,809
4. To re-elect Steve Bates as a Director of the Company.	10,959,335	98.60	156,096	1.40	11,115,431	4,561
5. To re-elect Geoff Hsu as a Director of the Company.	11,108,767	99.94	6,664	0.06	11,115,431	4,561
6. To re-elect Julia Le Blan as a Director of the Company.	10,950,996	98.52	164,435	1.48	11,115,431	4,561
7. To re-elect Dr Nicki Shepherd as a Director of the Company.						
	10,536,007	98.24	188,924	1.76	10,724,931	395,061
To re-elect The Rt Hon Lord Willetts as a Director of the Company.						
	9,871,903	92.04	853,447	7.96	10,725,350	394,642
9. To re-elect Roger Yates as a Director of the Company.	10,945,135	98.47	170,296	1.53	11,115,431	4,561
10. To re-appoint BDO LLP as auditor and to authorise the Audit Committee to determine their remuneration.						
	11,076,784	99.68	35,132	0.32	11,111,916	8,076
11. To approve and adopt the amended investment policy as the investment policy of the Company in substitution for,	44 400 500	00.07	2.550	0.02	44 407 050	40.000
and to the exclusion of, all previous investment policies of	11,103,500	99.97	3,556	0.03	11,107,056	12,936

the Company.						
12. To authorise the Directors to allot securities in the Company.						
	11,079,561	99.68	35,870	0.32	11,115,431	4,561
13#. To disapply the rights of pre-emption in relation to the allotment of securities.						
	11,068,162	99.58	47,108	0.42	11,115,270	4,722
14#. To authorise the Company to make market purchases of Ordinary shares in the Company.						
, ,	11,084,178	99.71	32,169	0.29	11,116,347	3,645
15#. That the Directors be permitted to hold General Meetings (excluding the AGM) on not less than 14 clear days' notice.						
,	11,090,838	99.78	24,538	0.22	11,115,376	4,616

- Special Resolution

Any proxy votes which are at the discretion of the Chairman have been included in the "For" total.

At the date of the AGM, the total number of Ordinary shares of 25p each in issue and the total number of voting rights was 37,247,029.

The proxy voting figures will shortly also be available on the Company's website at www.biotechgt.com

In accordance with Listing Rule 9.6.2, the full text of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Resolutions 11 to 15 will additionally be filed at Companies House.

27 July 2023

For further information please contact:

Katherine Manson Frostrow Capital LLP – Company Secretary

020 3709 8734

^{*} Please note that a 'vote withheld' is not a vote in law and is not counted in the calculation of the proportion of votes 'For' and 'Against' a resolution.